This week the FDA published a Federal Register notice announcing a formal review of testosterone replacement therapy for a new indication. The application deadline for manufacturers is April 30, 2026 — which makes this one of the more consequential near-term regulatory events for men tracking their hormonal health.
Here is what happened, what it might mean in practice, and what data is worth establishing now if this is relevant to you.
This article is informational only. It is not a recommendation to pursue TRT or any hormone therapy. Any decisions about testosterone treatment should be made in partnership with a licensed physician.
Current Approved Indication vs. What's Being Proposed
TRT has a well-defined approved use: hypogonadism in men with clinically low testosterone levels. In practice, this means a physician documents both a symptomatic presentation and lab values below a defined threshold — typically total testosterone below 300 ng/dL on two separate morning draws.
The proposed expansion under review would add low libido (hypoactive sexual desire) as a standalone qualifying symptom for men with hypogonadism. That is a meaningful clinical distinction. Under the current framework, a man must demonstrate clinically low T levels and the associated constellation of symptoms. Under the proposed expanded indication, low libido in a hypogonadal man could itself be the qualifying presenting symptom — rather than a secondary consideration after labs are already in range for treatment.
This matters because libido and testosterone track together imperfectly. Some men with borderline or low-normal testosterone experience significant reductions in sexual desire that don't manifest as other classic hypogonadal symptoms (fatigue, muscle loss, mood changes). The proposed indication would create a cleaner clinical pathway for that population.
What This Might Mean in Practice
A few realistic implications — framed carefully, because regulatory review does not equal approval.
More men may qualify for TRT prescriptions. If the expanded indication clears, physicians would have clearer regulatory footing for prescribing TRT to men whose primary documented complaint is low libido, rather than needing to build a case around a fuller symptom cluster.
Insurance coverage criteria may shift. Coverage decisions frequently track FDA-approved indications. A formal expansion could change the prior-authorization calculus for insurers who currently decline TRT claims for men whose labs are borderline but whose primary complaint is libido-related.
Timeline is genuinely unknown. Manufacturer applications are due April 30. From there, FDA review timelines vary widely — 12 to 24+ months is a reasonable range for a supplemental indication review. This is not imminent.
This does not affect compounded peptides or SERMs. If you are currently using or researching alternative approaches like enclomiphene or other SERMs, this regulatory action has no bearing on that landscape. Those compounds operate in a separate regulatory channel. See our post on enclomiphene and SERMs for context on those options.
The KYZATREX Note: TRT Has Already Modernized
One development worth knowing alongside this regulatory news: FDA-approved oral testosterone is now available. KYZATREX, a prescription oral testosterone undecanoate, launched in the US and has reported restoring testosterone levels in up to 96% of men in clinical data cited by its manufacturer. For men who have historically avoided TRT due to needle aversion, the delivery landscape is meaningfully different than it was even a few years ago. The modality conversation and the indication conversation are separate — but together they suggest the TRT space is in an active period of development.
What to Track Now
If you are interested in having an informed conversation with your physician about this topic, the most useful thing you can do is build a data baseline now. A 60–90 day tracking window gives any doctor a picture of your actual trends rather than a single snapshot.
Baseline metrics worth logging for 60–90 days:
- Morning total testosterone — from a bloodwork panel, ideally two draws on separate days
- Free testosterone — the bioavailable fraction; total T alone can be misleading if SHBG is elevated
- SHBG (sex hormone-binding globulin) — high SHBG can suppress free T even when total looks normal
- Libido self-rating (1–10 daily) — log at the same time each day for consistency
- Energy score (1–10 daily) — separate from libido; useful for distinguishing hormonal from sleep/stress causes
- HRV via wearable — a low-cost continuous proxy for autonomic and recovery status
Bring this log to your appointment. Physicians respond better to trend data than to a single subjective complaint.
Important Limitations
FDA review is not FDA approval. The review process can result in approval, rejection, or a request for additional data. There is no guarantee this indication expansion will clear, and no timeline has been published for a final decision.
This article is informational — it describes what regulators are reviewing and what the clinical distinction means. It is not a recommendation to pursue TRT, to change any current protocol, or to draw conclusions about your own health based on regulatory news.
Low libido has many potential causes beyond testosterone. Sleep deprivation, chronic psychological stress, relationship factors, prescription medications (particularly SSRIs and antihypertensives), thyroid dysfunction, elevated prolactin, and metabolic conditions can all significantly suppress sexual desire — independent of testosterone levels. Lab work and a physician evaluation are essential before attributing low libido to low T. Tracking your data is useful preparation for that conversation; it is not a substitute for it.
Frequently Asked Questions
Related: Enclomiphene, SERMs, and the New Wave Beyond TRT
Be the first to try Prova
We're building an app to track whether testosterone tracking actually works. Join the waitlist.